Chinese PLA General Hospital (CAR-T cell technology) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Chinese PLA General Hospital (CAR-T cell technology) General Information

Description

Biologic cancer therapy asset. The asset consists of Chimeric Antigen Receptor T cell (CAR-T) therapy, its recombinant expression vector CD19, CD20, CD30 and human epidermal growth factor receptor's immuno-oncology patents, and phase I/II clinical data of the therapies and manufacturing knowledge. The CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Cellular Biomedicine Group
Primary Office
  • 28 fuxing road
  • Beijing
  • China
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Chinese PLA General Hospital (CAR-T cell technology) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.

Request a free trial

Chinese PLA General Hospital (CAR-T cell technology) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Chinese PLA General Hospital (CAR-T cell technology)‘s full profile, request access.

Request a free trial